根治幽门螺杆菌三联疗法对冠心病患者内皮功能的影响

目的：根治探讨幽门螺杆菌（Hp）三联疗法对冠状动脉粥样硬化性心脏病（CHD）患者血管内皮功能的影响。方法纳入2010年10月～2013年2月大庆龙南医院院心内科住院14C尿素呼气试验（14C-UBT）阳性的冠心病患者104例，在常规治疗的基础上，进行根治Hp三联治疗（阿莫西林＋克拉霉素＋兰索拉唑），疗程为7天，研究期为6个月。研究对象在试验前后检测血脂、血栓素B2（TXB2）和6-酮前列腺素F1α（6-keto-PGF1α），并通过肱动脉内径变化S1进行内皮依赖性血管舒张功能（FMD）检测。结果治疗后患者的血浆总胆固醇（TC）、TXB2水平比治疗前明显降低[TC：（4.98±1.20） mmol/L vs.（5.43±1.87）mmol/L；TXB2：（240±41）pg/ml vs.（282±66）pg/ml]，6-keto-PGF1α、CI明显升高[6-keto-PGF1α：（299±69）pg/ml vs.（217±64）pg/ml；S1：（7.86±0.39）% vs.（4.87±0.26）%）]，差异有统计学意义（P＜0.05）。结论根治Hp三联疗法可改善合并Hp感染的冠心病患者血管内皮功能。

Influence of Helicobacter pylori eradicating therapy on endothelial function in patients with coronary heart disease

Objective To investigate the influence of triple therapy for eradicating Helicobacter pylori （Hp） on vascular endothelial function in the patients with coronary heart disease （CHD）. Methods The hospitalized CHD patients （n=104） with positive 14C-UBT were chosen from the Department of Cardiology of Daqing Longnan Hospital from Oct. 2010 to Feb. 2013. On the basis of routine treatment, the patients were given the triple therapy for eradicating Hp （amoxicillin＋clarithromycin＋lansoprazole） for 7 days and observed for 6 months. The levels of blood fat, thromboxane B2 （TXB2） and 6-keto-PGF1αwere detected before and after treatment. The endothelium-dependent flow-mediated dilation （FMD） was detected through observing the changes of brachial artery diameter （S1）. Results The levels of TC and TXB2 decreased significantly after treatment [TC：（4.98± 1.20） mmol/L vs. （5.43±1.87） mmol/L;TXB2：（240±41） pg/ml vs. （282±66） pg/mL], and 6-keto-PGF1αand CI increased significantly [6-keto-PGF1α：（299±69） pg/ml vs. （217±64） pg/mL;S1：（7.86±0.39）%vs. （4.87 ±0.26）%, P〈0.05]. Conclusion The triple therapy for eradicating Hp can ameliorate the vascular endothelial function in CHD patients with Hp infection.